Let's hope so. I can only hope that the plan, if it goes well, is to use the data to further expedite the trials as well. If we can continue to prove safety and also great efficacy with better vision patients, it wouldn't make sense to take a step "down" to worse vision patients.
The fact that they allowed the patients to be treated at once rather than one at a time is also re-assuring. It shows that the FDA must have a lot of confidence when it comes to safety. The folks with better vision have more to lose.
I suspect we have a lot to look forward to as these patients are treated.